Posted on 04/05/2010 in Scientific Beckman Coulter has expressed satisfaction with its business performance in the first quarter of 2010 after achieving strong results.
The biomedical testing specialist's revenue for the quarter was $881.1 million (579.5 million pounds), an increase of 27.4 per cent year-on-year, while operating income rose by 101.7 per cent in the same timeframe.
This was attributed to strong demand for immunoassay and flow cytometry products in international markets, as well as the relative weakness of the company's performance in early 2009.
Following the announcement of these results, Beckman Coulter has updated its full-year outlook and is now expecting its total revenue for 2010 to be between $3.8 billion and $3.9 billion.
Scott Garrett, chairman, president and chief executive officer of Beckman Coulter, said: "I remain confident about the soundness of our strategy and the stability and opportunities in our sector."
The company has also declared a dividend payout of 18 cents per share of outstanding common stock this week, with the amount to be payable on May 21st 2010.Other news stories from 04/05/2010
Read more in the Zenopa News Archive
How this news is generated
|
